CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients | Zendy

JeanSébastien Hulot | Zendy; JeanPhilippe Collet | Zendy; Guillaume Cayla | Zendy; Johanne Silvain | Zendy; Frédérick Allanic | Zendy; Anne Bellemain-Appaix | Zendy; Stuart A. Scott | Zendy; Gilles Montalescot | Zendy

Open Access

CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients

Author(s) -

JeanSébastien Hulot,

JeanPhilippe Collet,

Guillaume Cayla,

Johanne Silvain,

Frédérick Allanic,

Anne Bellemain-Appaix,

Stuart A. Scott,

Gilles Montalescot

Publication year - 2011

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.111.963025

Subject(s) - clopidogrel , medicine , cyp2c19 , pharmacodynamics , myocardial infarction , hazard ratio , pon1 , cardiology , confidence interval , ticlopidine , pharmacology , pharmacokinetics , genotype , biochemistry , cytochrome p450 , metabolism , gene , chemistry

Reduced concentrations of clopidogrel active metabolite have been associated with diminished platelet inhibition and higher rates of adverse cardiovascular events. Paraoxonase-1 (PON1) has recently been proposed as a key enzyme for clopidogrel metabolic activation. We tested the effects of PON1 polymorphisms on clopidogrel pharmacokinetics and pharmacodynamics and the occurrence of cardiovascular outcomes in young post-myocardial infarction (MI) patients treated with clopidogrel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research